New Anticoagulants and Their Role in VTE [CME] (UIP2013-18)
This course will examine oral direct thrombin/Xa inhibitors, management of bleeding complications and anticoagulant strategies for VTE and reducing post-thrombotic syndrome.
This course includes:
Steps to Successfully Complete This Activity
To participate in this educational activity please follow the steps listed below.
If you are new to the ACP Online Education Center we require that you register prior to viewing any activity. Click the Register link located in the top right corner of this screen to do so. If you are already a registered user log in and click the TAKE COURSE button that will appear in the Course Summary box.
- To begin the activity click the START COURSE button.
- Progress through course content by using the NEXT button.
- Complete all required items in the course.
- Participants must score 80% or greater on the Post-Test to advance and receive credit. They are given three attempts to meet this threshold.
- Track your progress using the Course Progress menu.
- On the final page of the activity a link will be provided to download your certificate.
The content of this activity is designed to meet the needs of the following target audience: phlebologists, general surgeons, vascular surgeons, interventional radiologists, interventional cardiologists, vascular medicine practitioners, dermatologists, dermatologic surgeons, family practice and internal medicine practitioners, plastic surgeons, obstetricians and gynecologists, cardiologists, and any other healthcare professional currently or planning on treating patients with venous disease.
As a result of this activity, the participant should be able to:
- Identify novel anticoagulants, their classes, and uses.
- Determine which individuals are candidates for using new anticoagulants.
- Recognize the limitations of novel anticoagulants.
|NAME||ROLE||COMMERCIAL INTEREST||TYPE OF RELATIONSHIP|
|Stephanie Dentoni, MD||Speaker/Content Reviewer||None||n/a|
|Heather Durband, BS||Staff||None||n/a|
|Antonio Gasparis, MD||Scientific Committee/Planner||Covidien; Cook; Vascular Insights; Gore||Consultant/Speaker|
|Kathleen Gibson, MD||Speaker||Sapheon; Iverson Genetics; Pfizer; Nycomed; Sigvaris||Consultant/Investigator|
|Jean-Jérôme Guex, MD, FACPh||Scientific Committee/Planner||Servier International; Thuasne; Vascular Insights||Speaker/Consultant; Scientific Committee Member|
|Russell Hull, MD||Speaker||Leo Pharma; Sanofi; Janssen||Researcher; Consultant; Consultant|
|Susan Kahn, MD, MSc||Speaker||None||n/a|
|Michelle McEvoy, MSN/Ed, RN||Content Reviewer||None||n/a|
|Mark Meissner, MD||Scientific Committee/Planner||None||n/a|
|Nick Morrison, MD, FACS, FACPh, RPhS||Scientific Committee/Planner||Medi; Merz; BTG; VenX||Speaker; Consultant; Principal Investigator; Scientific Advisory Board|
|Malay Patel, MD||Speaker||None||n/a|
|Melvin Rosenblatt, MD, FACPh||Scientific Committee/Planner||None||n/a|
|Sherry Scovell, MD||Content Reviewer||Bolton Medical PPD||Data Safety & Monitoring Committe Member|
|Thomas Wakefield, MD||Scientific Committee/Planner/Speaker||None||n/a|
|Steven Zimmet, MD, RVT, FACPh||Scientific Committee/Planner||Merz Aesthetics||Speaker|
The views and opinions expressed in this activity are those of the faculty and do not necessarily represent the views of the ACP. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting professional use of any of the information provided herein. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of ACP Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.
Discussion of Off-Label Use
Although no longer required by the Accreditation Council for Continuing Medical Education (ACCME), ACP CME requests all faculty to inform learners of any products they will discuss that are off-label or investigational.
Reproduction of this material is not permitted without written permission from the copyright owner.
Review & Recertification
This course was reviewed and recertified for AMA PRA Category 1 CreditTM in March 2015 and February 2017.
- 1.50 AMA PRA Category 1 Credit™
- 1.50 Attendance